Oils having antibacterial activity
Inventors
Bischoff, Kenneth M. • Leathers, Timothy D. • Price, Neil P. • MANITCHOTPISIT, Pennapa
Assignees
US Department of Agriculture USDA
Publication Number
US-10544085-B2
Publication Date
2020-01-28
Expiration Date
2035-03-16
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Abstract
Compounds, called liamocins from Aureobasidium pullulans, having the general structure in Formula 1 are disclosed. where R1 is either COCH3 or H; and R2 is between two to ten O-linked 3,5-dihydroxydecanoate; and R3 can be a polyol (e.g., L- or D-glycerol, L- or D-threitol, L- or D-erythritol, L- or D-arabitol, L- or D-xylitol, L- or D-lyxitol, L- or D-ribitol, L- or D-allitol, L- or D-altritol, L- or D-mannitol, L- or D-iditol, L- or D-gulitol, L- or D-glucitol (also called sorbitol), L- or D-galactitol (also called dulcitol), and L- or D-talitol), 2-amino-D-mannitol, 2N-acetylamino-D-mannitol, L-rhamnitol, or D-fucitol; except when R3 is D-mannitol, R2 is not 2 nor 3 O-linked 3,5-dihydroxydecanoate chains. These liamocins described above in addition to D-mannitol liamocin A1, D-mannitol liamocin A2, D-mannitol liamocin B1, and D-mannitol liamocin B2, alone or in combination with each other, can be used to kill certain bacteria and to treat certain bacterial infections.
Core Innovation
This invention relates to novel oils and their components produced by Aureobasidium pullulans, called liamocins, which possess antibacterial activity. The invention includes isolated compounds having the general structure of Formula 1, where R1 is either COCH3 or H; R2 is between two to ten O-linked 3,5-dihydroxydecanoate; and R3 is a polyol such as glycerol, threitol, erythritol, arabitol, mannitol, and others. Compositions containing these liamocins, alone or in combination, can be used to kill certain bacteria and treat bacterial infections.
The problem addressed by the invention is the need for new methods and compositions to prevent or treat infections caused by Streptococcus species and other bacteria. Current treatments, such as systemic antibiotic administration in dairy cattle to reduce mastitis during the non-lactating period, pose food safety risks and contribute to antibiotic resistance. Therefore, there is a need for chemical compounds and compositions that can kill or inhibit bacterial growth, especially for Streptococcus species, when applied to animals or surfaces.
Claims Coverage
The patent discloses four main inventive features centered on methods of preventing bacterial diseases using compositions containing specific liamocin compounds, modes of administration, and applicable animal types.
Method of preventing diseases caused by specified Streptococcus species
A method of preventing disease caused by Streptococcus agalactiae, infantarius, mitis, mutans, pneumonia, salivarius, suis, or uberis by administering an effective amount of a composition to prevent bacterial growth on or in an animal susceptible to the disease. The composition comprises one or more compounds of Formula 1, optionally with a carrier and diluent, where Formula 1 specifies liamocins with defined chemical structure.
Selection of liamocin compounds with specific polyol head groups
The composition's compound of Formula 1 is selected from a group comprising L- or D-mannitol liamocins A1, A2, B1, B2; L- or D-arabitol liamocins A1, A2, B1, B2; L- or D-threitol liamocins A1, A2, B1, B2; and L- or D-glycerol liamocins A1, A2, B1, B2.
Multiple routes of administration for the composition
The administering of the composition can occur via topical, oral, or parenteral routes to the animal.
Applicability to a broad range of animals
The composition can be administered to animals selected from mammals, birds, fish, amphibians, or reptiles.
The claims cover methods of preventing Streptococcus-related diseases in various animals by administering compositions containing specific liamocins with defined chemical structures and routes of administration.
Stated Advantages
Liamocins and compositions containing them have antibacterial activity effective against Streptococcus spp., Enterococcus spp., and Bacillus spp.
The liamocins can be used as topical disinfectants, transdermal antibacterial agents, and systemically administered antibacterial agents.
The compositions remain effective after heat sterilization procedures like autoclaving.
Liamocins produced have structural diversity depending on culturing conditions, potentially allowing tailored antibacterial activity.
The antibacterial activity includes bactericidal effects with rapid loss of bacterial membrane integrity and viability.
Documented Applications
Use as a topical disinfectant to kill or inhibit growth of Streptococcus spp. and other susceptible bacteria on animal surfaces and article surfaces such as counters, walls, floors, medical instruments, fruits, vegetables, and foods including meat and fish.
Treatment of bacterial diseases caused by Streptococcus spp., Enterococcus spp., and Bacillus spp. in mammals, birds, fish, amphibians, and reptiles.
Use in teat dips containing liamocin-containing oil to reduce bacterial infections such as bovine mastitis.
Development of mouthwashes containing liamocin-containing oil or purified liamocin compounds to reduce Streptococcus mutans populations in humans.
Interested in licensing this patent?